0 seconds of 2 minutes, 42 secondsVolume 0%
Press shift question mark to access a list of keyboard shortcuts
00:00
02:42
02:42
 
  • Algernon Pharmaceuticals has reported positive results from the complete data set of its Phase 2a Study evaluating NP-120 for the treatment of idiopathic pulmonary fibrosis and chronic cough
  •  All of the data showed positive results, including statistically significant improvements in measures of cough
  • Christopher J. Moreau, CEO of Algernon Pharmaceuticals, sat down with Daniella Atkinson to discuss the update
  • Algernon is a drug re-purposing company that investigates safe, already approved drugs, and naturally occurring compounds, for new disease applications
  • Algernon Pharmaceuticals Inc. (AGN) opened trading at C$5.39per share

Algernon Pharmaceuticals (AGN) has reported positive results from the complete data set of its Phase 2a Study evaluating NP-120 (“Ifenprodil”).

Ifenprodil is being evaluated for the potential treatment of idiopathic pulmonary fibrosis (“IPF”) and chronic cough.

The full data set includes additional secondary measures of efficacy, including both objective measurement of lung function and patient-reported outcomes of both IPF and cough.

All of the data showed positive results, including statistically significant improvements in measures of cough.

Christopher J. Moreau, CEO of Algernon Pharmaceuticals, sat down with Daniella Atkinson to discuss the update.

“This data, when added to the topline data already reported, now provides a more complete picture that shows just how effective Ifenprodil was in this Phase 2a study. We look forward to presenting the data to the U.S FDA, including applying for orphan designation, the filing of a pre-IND application for a Phase 2b IPF with cough trial, as well as an application for Breakthrough Therapy designation.”

Algernon is a drug re-purposing company that investigates safe, already approved drugs for new disease applications.

Algernon Pharmaceuticals Inc. (AGN) opened trading at C$5.39.


More From The Market Online
Stock image generated with AI

@ the Bell: Markets grow in the face of energy and mining gains

Canada’s main stock index climbed on Monday, driven by gains in energy and mining shares. US stocks show signs of stability early in the…
Willow Biosciences logo

Willow Biosciences to sell operating subsidiary Epimeron USA Inc.

Willow Biosciences (TSX:WLLW) announced a definitive agreement to sell its wholly-owned operating subsidiary, Epimeron USA Inc.
ai generated stock image

@ the Bell: TSX ends rough week on a positive note with new PM

Canada’s main stock index rallied on Friday, yet the benchmark index experienced a significant weekly decline
ai generated stock image

@ the Bell: TSX struggles as trade war intensifies

Canada’s main stock index slid lower on Thursday during turbulent trading, as investors stayed cautious as the US trade conflict escalates.